High Prevalence of Iron Overload in Adult Allogeneic Hematopoietic Cell Transplant Survivors  by Majhail, Navneet S. et al.
High Prevalence of Iron Overload in Adult Allogeneic
Hematopoietic Cell Transplant Survivors
Navneet S. Majhail,1 Todd DeFor,1 Hillard M. Lazarus,2 Linda J. Burns1
1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota; and 2Comprehensive
Cancer Center of Case Western Reserve University, Cleveland, Ohio
Correspondence and reprint requests: Navneet S. Majhail, MD, MS, Division of Hematology, Oncology and
Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455 (e-mail: majha001@umn.edu).
Received March 18, 2008; accepted April 18, 2008
Allogeneic hematopoietic cell transplant (HCT) recipients frequently need red blood cell transfusions, and can
be at risk for developing iron overload. We studied the prevalence of iron overload in 56 adult allogeneic HCT
patients who had survived for a median of 28 (range: 12-151) months from transplant. Patients were initially
screened with serum ferritin, and those with serum ferritin .1000 ng/mL underwent R2 magnetic resonance
imaging (MRI) of the liver, a sensitive and specific noninvasive imaging technique to measure liver iron concen-
tration (LIC). Iron overload was defined as LIC above normal (.1.8 mg/g dry weight). Nineteen patients had
serum ferritin .1000 ng/mL with a median LIC of 7.0 (range: 1.8-28.3) mg/g. The overall prevalence of iron
overload was 32% (95% confidence intervals, 20%-46%). The LIC on MRI was moderately correlated with se-
rum ferritin (r 5 .47). Iron overload is a frequent complication of allogeneic transplantation. Serum ferritin is
a good screening test but does not reliably predict tissue iron overload, and estimation of LIC should be consid-
ered before initiating therapy. More studies are needed to determine the impact of iron overload on long-term
morbidity and mortality in allogeneic transplant survivors.
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Iron overload is a well-recognized cause of long-
term morbidity and mortality in transfusion-depen-
dent anemias such as thalassemia and sickle cell
disease [1-3]. Allogeneic hematopoietic cell transplant
(HCT) recipients frequently require red blood cell
(RBC) transfusions, and pretransplant hyperferritine-
mia has been recently associated with an increased
risk of early nonrelapse mortality (NRM) [4,5]. Trans-
fusion-related iron overload is considered to be a com-
plication of HCT, and recently published consensus
guidelines recommend screening for iron overload in
all transplant survivors [6]. However, the burden of
late posttransplant iron overload and its clinical
impact has not been well characterized. Therefore,
we conducted a study to determine the prevalence of
iron overload in long-term adult survivors of alloge-
neic HCT.790METHODS
Allogeneic HCT survivors followed at the Univer-
sity of Minnesota Blood and Marrow Transplant pro-
gram were eligible for this study if they met all of the
following criteria: (1) survived $1 year from HCT,
(2) were$18 years of age at HCT, (3) had no contrain-
dication for magnetic resonance imaging (MRI), and
(4) had no uncontrolled infections. Patients were eligi-
ble regardless of whether they needed ongoing RBC
transfusions. Patients with chronic graft-versus-host-
disease (cGVHD) on a stable or tapering immunosup-
pressive regimen were eligible; however, those with
worsening GVHD were excluded. The study protocol
was approved by the institutional review board, and all
participants provided informed consent prior to enroll-
ment. Consecutive patients who had survived $1 year
from HCT and were returning for follow-up at our
center were approached for participation in the study.
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on this study using serum ferritin (normal range:
20-300 ng/mL). Those with serum ferritin of .1000
ng/mL underwent anMRI of the liver to estimate liver
iron concentration (LIC, normal range: 0.17-1.8 mg/g
dry tissue). The MRI measurement of LIC was based
on the imaging of proton transverse relaxation rates
(R2) within the liver using a 1.5T MRI machine (Sie-
mens MAGNETOM Avanto, Malvern, PA). Compar-
ative studies with liver biopsy and biomagnetic
susceptometry using superconducting quantum inter-
ference device (SQUID) have shown this noninvasive
R2 MRI technique (FerriScan, Perth, Australia) to
be highly sensitive and specific for estimating LIC
[7-9]. Iron overload was defined as LIC above the nor-
mal range on MRI of the liver (.1.8 mg/g). Blood
transferrin saturation (normal range: 20%-55%), bili-
rubin (normal range: 0.2-1.3 mg/dL), aspartate amino-
transferase (AST, normal range: 0-55 U/L), alanine
aminotransferase (ALT, normal range: 0-70 U/L),
and alkaline phosphatase (normal range: 40-150 U/L)
were also measured in all patients.
Details regarding diagnosis and transplantation
were obtained from our Blood andMarrowTransplant
Program database, which prospectively collects data
on all HCT patients at our institution. The number
of RBC transfusions administered since initial diagno-
sis of underlying hematologic disorder was obtained
from our or referring institutions Blood Bank. Patients
who had a history of but no current symptoms or signs
of cGHVD and had been off immunosuppressant drug
therapy for at least 6 months were classified as resolved
GVHD.
The primary endpoint of this study was to estimate
the prevalence of iron overload in$1 year survivors of
allogeneic HCT. Secondary endpoints were to deter-
mine the correlation between LIC on R2 MRI and
serum ferritin and transferrin saturation in patients
with elevated ferritins. Patient and transplant charac-
teristics were compared using chi-square, Fisher’s
exact, or Wilcoxon’s rank sum test, as appropriate.
Relationships between LIC and ferritin and transferrin
saturation were explored using Spearman’s rank corre-
lation (r). All tests were 2 tailed, and a P-value of\.05
was considered to be statistically significant. Analysis
was conducted on SPSS software (version 10.0,
Chicago, IL).
RESULTS
Seventy-two allogeneic HCT recipients were
approached for participation in this study. Twelve
patients either refused participation (N 5 5) or were
not eligible for enrollment (disease relapse, 4; uncon-
trolled GVHD, 1; uncontrolled infection, 1; contrain-
dication for MRI , 1). The median age at HCT and
duration of follow-up since HCT were similarbetween patients who enrolled and did not enroll on
this study. The diagnoses of patients who did not
participate included non-Hodgkin lymphoma (NHL;
N 5 3), acute myelogenous leukemia (AML; N 5 2),
chronic myelogenous leukemia (CML; N5 2), Hodg-
kin lymphoma (HL; N 5 2), multiple myeloma (MM;
N 5 2) and chronic lymphocytic leukemia (N 5 1).
Sixty patients were enrolled in this study. Four
patients did not complete study evaluations after sign-
ing consent and were excluded from further analysis.
All 56 eligible patients were transfusion independent
at the time of study enrollment. For the whole cohort,
median age at enrollment was 51 (range: 24-69) years
and patients were a median of 28 (range: 12-151)
months since transplantation.
Serum ferritin of .1000 ng/mL was present in 19
(34%) patients (Table 1). Compared to patients with-
out an elevated ferritin, patients with serum ferritin of
.1000 ng/mLweremore likely to have acute leukemia
or myelodysplastic syndrome (MDS; 68% versus 30%,
P5 .02) and had received more RBC transfusions (me-
dian 24 versus 6, P\ .01).
Among the 19 patients with serum ferritin .1000
ng/mL, 18 had iron overload on R2 MRI (LIC .1.8
mg/g), with a resultant overall prevalence rate of
32% (95% confidence intervals [CI], 20%-46%).
LIC .5 mg/g was present in 13 patients (23% [95%
CI, 13%-36%]). Among 33 patients with .2-year
post-HCT follow-up, 12 (36%) had iron overload
compared to 6 of 23 (26%) patients with #2 year fol-
low-up (P 5 .42). Also, there was no difference in the
proportion of patients with iron overload among re-
cipients of myeloablative and reduced-intensity condi-
tioning (RIC; 36% versus 26%, P 5 .42), related and
unrelated donor grafts (30% versus 37%, P 5 .59),
or active and resolved cGVHD (26% versus 44%,
P 5 .41).
Six patients with LIC .5 mg/g underwent hemo-
chromatosis mutation analysis using a buccal swab
sample at the discretion of their transplant physician.
Among these, 2 were found to be heterozygous for
the C282Y mutation.
Although, hepatic or cardiac dysfunction was ob-
served in 5 patients with elevated LIC, organ toxicity
could be attributed to iron overload in only 2 patients.
Among these 5 patients, 3 had abnormal liver function
tests.Twohadabnormal values thatwerewithin2 times
the upper limit of normal and could be attributed
to medications. One patient with known cutaneous
cGVHD on a stable immunosuppression regimen had
blood alkaline phosphatase of 533 U/L but normal
levels of bilirubin, AST, and ALT. Ferritin and LIC
were 3502 ng/mL and 9 mg/g, respectively, and iron
overload was considered to be the cause of her elevated
alkaline phosphatase, which progressively decreased to
197 U/L after 4 phlebotomy sessions. Clinically evi-
dent congestive heart failure was present in 2 patients.
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Characteristic Serum Ferritin #1000 ng/mL (N 5 37) Serum Ferritin .1000 ng/mL (N 5 19) P-Value
Median age (range), years 52 (29-65) 49 (24-69) .44
Median time since HCT (range), months 33 (12-151) 25 (12-122) .22
Males 20 (54%) 12 (63%) .51
Diagnosis .02
Acute leukemia/MDS* 11 (30%) 13 (68%)
Non-Hodgkin lymphoma 13 (35%) 3 (16%)
Other† 13 (35%) 3 (16%)
Conditioning regimen .30
Myeloablative 20 (54%) 13 (68%)
Reduced intensity 17 (46%) 6 (32%)
Graft source .18
Matched related donor 25 (68%) 12 (63%)
Matched unrelated donor 1 (3%) 3 (16%)
Umbilical cord blood 11 (30%) 4 (21%)
Chronic graft-versus-host disease .20
None or resolved‡ 14 (38%) 4 (21%)
Current 23 (62%) 15 (79%)
Abnormal liver function tests§ 7 (19%) 3 (16%) .77
Median RBC transfusions (range)¶ 6 (0-35) 24 (11-41) \.01
Median transferring saturation (range), % 23 (8-45) 33 (10-76) \.01
Median ferritin (range), ng/mL 291 (52-991) 1508 (1003-7311)
Median LIC (range), mg/g dry weight ND§ 7.0 (1.8-28.3)
HCT indicates hematopoietic cell transplantation; MDS, myelodysplastic syndrome; RBC, red blood cell; ND, not done; LIC, liver iron
concentration.
*Includes 1 patient with acute lymphoblastic leukemia.
†Sixteen patients with ‘‘other’’ diagnoses included: chronic myelogenous leukemia, 8; multiple myeloma, 4; Hodgkin lymphoma, 2; chronic lym-
phocytic leukemia, 1; myelofibrosis, 1.
‡Resolved cGVHD was defined as discontinuation of all immunosuppressive therapy for at least 6 months.
§Defined as abnormal serum bilirubin, alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.
¶RBC transfusions since diagnosis of underlying malignancy.
§Not done per protocolThe first, with LIC of 15.8 mg/g, presented with unex-
plained heart failure. An extensive workup including
right and left heart catheterization revealed no discern-
ible etiology.Although cardiac imaging to evaluate iron
accumulation in the heart was not done, iron overload
was considered to be a contributing factor for her car-
diac dysfunction, which improved with initiation and
optimization of cardiac medications and phlebotomy.
The second patient had LIC of 2.8 mg/g; however,
heart failure was attributed to his previously diagnosed
restrictive pericarditis.
Serum ferritin was moderately correlated with LIC
(r 5 .47, p 5 .04) (Figure 1A). Similarly, a moderate
correlation was observed between transferrin satura-
tion and LIC (r 5 .46, P 5 .05) (Figure 1B).
DISCUSSION
We observed a relatively high prevalence of iron
overload in long-term survivors of allogeneic HCT,
emphasizing the need for routine screening for iron
overload in this population.
Reports of iron overload after allogeneic HCT are
largely limited to case series or have only used ferritin as
a marker for body iron content [10-12]. Only 1 other
study has systematically evaluated iron overload inadult allogeneic HCT survivors and reported a similar
high prevalence [13]. In this cross-sectional study by
Rose et al. [13], 38 of 65 (58%) allogeneic HCT recip-
ients surviving amedian of 9 years since their transplant
had above normal ferritin (median ferritin for whole
cohort was 532 [range: 42-4203] mg/L). T2* MRI of
the liver, albeit not validated for hepatic iron estima-
tion, was done in 32 patients with elevated ferritin,
and of these 31 had increased LIC (median 117
mmol/g [6.5 mg/g]).
Serum ferritin has been shown to be a good test for
screening for iron overload but a poor predictor of
LIC in multiple studies in patients with thalassemia
and sickle cell disease [1,14-19]. Our study demon-
strates the poor predictive value of ferritin for estimat-
ing LIC in adult HCT survivors. Variability in ferritin
levels because of ineffective hematopoiesis or underly-
ing inflammation or infection could explain the lack of
this association. Although a useful test for initial
screening of iron overload in transplant recipients, se-
rum ferritin is not a reliable indicator of total body iron
burden. Therefore, attempts should be made to deter-
mine LIC in HCT survivors with elevated serum ferri-
tin prior to initiating therapy for iron overload. Besides
this study, other recent reports have described the use
of various liver MRI techniques for estimating LIC in
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of iron overload noninvasively [13,20]. We used the
R2 MRI technique (FerriScan) for estimating LIC
in this study. This is relatively simple to setup and in-
volves calibrating a standard 1.5T MRI machine with
the proprietary FerriScan software. Images of the liver
are then transmitted and analyzed centrally by the soft-
ware and a report listing the LIC is generated and sent
back to the investigators.
Only 2 patients with elevatedLIChad clinically sig-
nificant end-organ damage that could be attributed to
iron overload. Because iron-induced organ toxicity typ-
ically manifests after years of developing iron overload
[1], the relatively short follow-up of our cohort could
explain the lack of iron-associated comorbidities. Fur-
thermore, the natural history of transfusional iron over-
load in patients who become transfusion independent is
notwell characterized. Slowbut steadydecreases inLIC
over time have been observed in children with thalasse-
mia cured after allogeneic HCT, especially if they have
received adequate chelation therapy and have no liver
fibrosis pretransplant [21,22].
Figure 1. Relation between liver iron concentration and ferritin (A)
and transferrin saturation (B) (r is the Spearman’s rank correlation
coefficient). Liver iron concentration was estimated using R2 MRI
in patients with ferritin .1000 ng/mL.Our study has some limitations. We excluded pa-
tients with worsening GVHD. Selection bias could
also have been introduced because our study cohort
was a convenience sample since follow-up beyond
2 years posttransplant at our center in patients without
GVHD is at the discretion of the primary transplant
physician. However, a similar prevalence of iron over-
load was observed among patients surviving less than
and longer than 2 years and among those with and
without active cGVHD. Also, liver MRIs were not
performed in patients with ferritin levels #1000
ng/mL. Iron overload might have been missed in
patients with ferritin levels that were above normal
but \1000 ng/mL, and as a result, we might have
underestimated the true prevalence of iron overload.
However, few patients with transfusion-dependent
anemias and ferritin #1000 ng/mL have significantly
elevated LIC [1,19,23].
Notwithstanding these limitations our study raises
important issues about iron overload in HCT survi-
vors. The current paradigm of management of post-
transplant iron overload is largely based on
experience with transfusion dependent anemias and
MDS. LICs .5 to 7 mg/g are considered to herald
body iron levels high enough to cause end-organ dam-
age and necessitate the initiation of iron chelation
therapy [1]. Although measurement of LIC is recom-
mended, it is typically not done in routine clinical
practice because of the invasive nature of liver biopsy
and the limited availability of SQUID. Iron chelation
therapy is generally initiated for persistent elevation
of serum ferritin in the setting of ongoing transfusion
therapy. However, the majority of HCT survivors, un-
like patients with transfusion-dependent anemias, do
not need long-term transfusion support after recover-
ing from the early posttransplant period. This impor-
tant difference underscores the need to ascertain body
iron levels by measuring LIC, especially with the avail-
ability of noninvasive MRI techniques, before initiat-
ing iron chelation therapy or phlebotomy instead of
relying on ferritin alone and highlights the need to
conduct future investigations of the evolution of iron
overload following transplantation.
In summary, our study demonstrates that iron
overload is a relatively common complication in
long-term HCT survivors. Serum ferritin is a good
screening test, but estimation of LIC should be consid-
ered before initiating therapy for iron overload. More
studies are needed to better define the natural history
of iron overload and its impact on late morbidity and
mortality in this population.
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